Angelique Nadine Voorberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Angelique Nadine Voorberg has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Marie Louise Anna Schuttelaar
Department of Dermatology, University Medical Center Groningen, University of Groningen , Groningen
15 shared publications - Jart Ate Franke Oosterhaven
Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands
7 shared publications Geertruida L. E. Romeijn
Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands
3 shared publications- Marjolein de Bruin-Weller
Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht Utrecht The Netherlands
3 shared publications - Fieke M. Rosenberg
Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands
2 shared publications - Geertruida L. E. Romeijn
Department of Dermatology, University Medical Centre Groningen, University of Groningen , Groningen , The Netherlands
2 shared publications
Latest Publications
- Open Access
- 30 March 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 476
Transcriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema
Vesicular hand eczema (VHE), a clinical subtype of hand eczema (HE), showed limited responsiveness to alitretinoin, the only approved systemic treatment for severe chronic HE. This emphasizes the need for alternative treatment approaches. Therefore, our study aimed to identify drug repurposing opportunities for VHE using transcriptomics and genomics data. We constructed a gene network by combining 52 differentially expressed genes (DEGs) from a VHE transcriptomics study with 3 quantitative trait locus (QTL) genes associated with HE. Through network analysis, clustering, and functional enrichment analyses, we investigated the underlying biological mechanisms of this network. Next, we leveraged drug–gene interactions and retrieved pharmaco-transcriptomics data from the DrugBank database to identify drug repurposing opportunities for (V)HE. We developed a drug ranking system, primarily based on efficacy, safety, and practical and pricing factors, to select the most promising drug repurposing candidates. Our results revealed that the (V)HE network comprised 78 genes that yielded several biological pathways underlying the disease. The drug–gene interaction search together with pharmaco-transcriptomics lookups revealed 123 unique drug repurposing opportunities. Based on our drug ranking system, our study identified the most promising drug repurposing opportunities (e.g., vitamin D analogues, retinoids, and immunomodulating drugs) that might be effective in treating (V)HE.
- 30 March 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 476
Open AccessTranscriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema
Vesicular hand eczema (VHE), a clinical subtype of hand eczema (HE), showed limited responsiveness to alitretinoin, the only approved systemic treatment for severe chronic HE. This emphasizes the need for alternative treatment approaches. Therefore, our study aimed to identify drug repurposing opportunities for VHE using transcriptomics and genomics data. We constructed a gene network by combining 52 differentially expressed genes (DEGs) from a VHE transcriptomics study with 3 quantitative trait locus (QTL) genes associated with HE. Through network analysis, clustering, and functional enrichment analyses, we investigated the underlying biological mechanisms of this network. Next, we leveraged drug–gene interactions and retrieved pharmaco-transcriptomics data from the DrugBank database to identify drug repurposing opportunities for (V)HE. We developed a drug ranking system, primarily based on efficacy, safety, and practical and pricing factors, to select the most promising drug repurposing candidates. Our results revealed that the (V)HE network comprised 78 genes that yielded several biological pathways underlying the disease. The drug–gene interaction search together with pharmaco-transcriptomics lookups revealed 123 unique drug repurposing opportunities. Based on our drug ranking system, our study identified the most promising drug repurposing opportunities (e.g., vitamin D analogues, retinoids, and immunomodulating drugs) that might be effective in treating (V)HE.
- Open Access
- 19 October 2023
- Published by Wiley in Contact Dermatitis
- Vol. 90 (1) , 23-31
Transcriptional differences between vesicular hand eczema and atopic dermatitis
Background: Transcriptome analyses of vesicular hand eczema (VHE) indicated a large overlap with atopic dermatitis (AD). However, differentially expressed genes (DEGs) that differentiate VHE from AD are unknown.Objective: To identify distinctive transcriptional features of VHE in comparison to AD.Methods: We re‐analysed RNA sequencing data of 10 lesional palmar VHE epidermal biopsies and performed DEG analyses. We adjusted the obtained DEG results of 57 lesional whole AD skin biopsies of the upper extremities or trunk to our criteria. Up‐ and down‐regulated DEGs in both skin diseases, VHE‐only, AD‐only, and opposite regulated DEGs were identified. Enrichment analyses and Chi‐squared tests were conducted to test for differences in gene set enrichment between both skin diseases.Results: Comparing 3028 DEGs in VHE (1645 up; 1383 down) with 5391 DEGs in AD (3842 up; 1549 down), revealed 1516 shared DEGs (1179 up; 337 down) and 1512 DEGs unique to VHE (466 up, 1046 down). Interferon signalling and necroptosis were significantly more prominent in VHE compared to AD. Downregulated genes identified only in VHE (like DNASE1L2, KRT2, KRT9 and KRT25) indicate an aberrant epidermal differentiation.Conclusion: Our study indicates a common pathophysiology between VHE and AD, but also reveals transcriptional differences between VHE and AD.
- 19 October 2023
- Published by Wiley in Contact Dermatitis
- Vol. 90 (1) , 23-31
Open AccessTranscriptional differences between vesicular hand eczema and atopic dermatitis
Background: Transcriptome analyses of vesicular hand eczema (VHE) indicated a large overlap with atopic dermatitis (AD). However, differentially expressed genes (DEGs) that differentiate VHE from AD are unknown.Objective: To identify distinctive transcriptional features of VHE in comparison to AD.Methods: We re‐analysed RNA sequencing data of 10 lesional palmar VHE epidermal biopsies and performed DEG analyses. We adjusted the obtained DEG results of 57 lesional whole AD skin biopsies of the upper extremities or trunk to our criteria. Up‐ and down‐regulated DEGs in both skin diseases, VHE‐only, AD‐only, and opposite regulated DEGs were identified. Enrichment analyses and Chi‐squared tests were conducted to test for differences in gene set enrichment between both skin diseases.Results: Comparing 3028 DEGs in VHE (1645 up; 1383 down) with 5391 DEGs in AD (3842 up; 1549 down), revealed 1516 shared DEGs (1179 up; 337 down) and 1512 DEGs unique to VHE (466 up, 1046 down). Interferon signalling and necroptosis were significantly more prominent in VHE compared to AD. Downregulated genes identified only in VHE (like DNASE1L2, KRT2, KRT9 and KRT25) indicate an aberrant epidermal differentiation.Conclusion: Our study indicates a common pathophysiology between VHE and AD, but also reveals transcriptional differences between VHE and AD.
- Open Access
- 12 May 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (4) , 400-409
Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study
Background: Effective treatment options for patients with chronic hand eczema (CHE) are scarce. Dupilumab is licensed for the treatment of moderate-to-severe atopic dermatitis and has shown promising results for the treatment of hand eczema in other studies. Objectives: To evaluate the efficacy and safety of dupilumab in adult patients with severe CHE (subtypes recurrent vesicular hand eczema or chronic fissured hand eczema) who have an inadequate response/intolerance to alitretinoin, or when alitretinoin is medically inadvisable. Methods: In this 16-week, randomized, double-blind, placebo-controlled proof-of-concept phase IIb trial, patients with severe CHE were randomized 2 : 1 to dupilumab 300 mg or placebo subcutaneously every 2 weeks. Patients visited the outpatient clinic at the initiation of the study drug, and every 4 weeks until 16 weeks of treatment. The primary endpoint was the proportion of patients achieving at least a 75% improvement on the Hand Eczema Severity Index score (HECSI-75) at week 16. Adverse events were monitored during each visit. The study was registered on ClinicalTrials.gov (identifier NCT04512339). Results: In total, 30 patients were randomized, and 29 patients received the assigned study drug (dupilumab n = 20, placebo n = 9). At week 16, more patients achieved HECSI-75 in the dupilumab group than in the placebo group {95% [95% confidence interval (CI) 73.1–99.7] vs. 33% [95% CI 9.0–69.1]}. Dupilumab also showed greater least square mean percentage change from baseline to week 16 in peak pruritus Numerical Rating Scale compared with placebo [−66.5 ± 10.7 (95% CI −88.6 to −44.5) vs. −25.3 ± 17.0 (95% CI −60.1–9.4)]. Adverse events were similar for the dupilumab and placebo groups and were mostly mild. There were no serious adverse events, nor did any of the adverse events lead to discontinuation of the study drug. Conclusions: Dupilumab was efficacious and well tolerated. Larger studies of longer duration are needed to provide more evidence on the efficacy of dupilumab in CHE. Moreover, larger studies could also enable comparisons between clinical subtypes or aetiological diagnoses.
- 12 May 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (4) , 400-409
Open AccessEfficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study
Background: Effective treatment options for patients with chronic hand eczema (CHE) are scarce. Dupilumab is licensed for the treatment of moderate-to-severe atopic dermatitis and has shown promising results for the treatment of hand eczema in other studies. Objectives: To evaluate the efficacy and safety of dupilumab in adult patients with severe CHE (subtypes recurrent vesicular hand eczema or chronic fissured hand eczema) who have an inadequate response/intolerance to alitretinoin, or when alitretinoin is medically inadvisable. Methods: In this 16-week, randomized, double-blind, placebo-controlled proof-of-concept phase IIb trial, patients with severe CHE were randomized 2 : 1 to dupilumab 300 mg or placebo subcutaneously every 2 weeks. Patients visited the outpatient clinic at the initiation of the study drug, and every 4 weeks until 16 weeks of treatment. The primary endpoint was the proportion of patients achieving at least a 75% improvement on the Hand Eczema Severity Index score (HECSI-75) at week 16. Adverse events were monitored during each visit. The study was registered on ClinicalTrials.gov (identifier NCT04512339). Results: In total, 30 patients were randomized, and 29 patients received the assigned study drug (dupilumab n = 20, placebo n = 9). At week 16, more patients achieved HECSI-75 in the dupilumab group than in the placebo group {95% [95% confidence interval (CI) 73.1–99.7] vs. 33% [95% CI 9.0–69.1]}. Dupilumab also showed greater least square mean percentage change from baseline to week 16 in peak pruritus Numerical Rating Scale compared with placebo [−66.5 ± 10.7 (95% CI −88.6 to −44.5) vs. −25.3 ± 17.0 (95% CI −60.1–9.4)]. Adverse events were similar for the dupilumab and placebo groups and were mostly mild. There were no serious adverse events, nor did any of the adverse events lead to discontinuation of the study drug. Conclusions: Dupilumab was efficacious and well tolerated. Larger studies of longer duration are needed to provide more evidence on the efficacy of dupilumab in CHE. Moreover, larger studies could also enable comparisons between clinical subtypes or aetiological diagnoses.
- 18 April 2023
- Published by University of Groningen Press
Hand eczema: from pathogenesis to novel treatments
- 18 April 2023
- Published by University of Groningen Press
Hand eczema: from pathogenesis to novel treatments
- Open Access
- 1 June 2022
- Published by Wiley in Contact Dermatitis
- Vol. 87 (4) , 366-368
Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: Results from a prematurely discontinued randomized controlled trial
- 1 June 2022
- Published by Wiley in Contact Dermatitis
- Vol. 87 (4) , 366-368
Open AccessEfficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: Results from a prematurely discontinued randomized controlled trial
- Open Access
- 24 April 2022
- Published by Wiley in Contact Dermatitis
- Vol. 87 (2) , 185-191
The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry
Background: The hands are a common predilection site of atopic dermatitis (AD). Dupilumab is licensed for the treatment of AD but not for chronic hand eczema (CHE), while CHE is challenging to treat.Objectives: To evaluate the long‐term effect of dupilumab on hand eczema (HE) in patients with AD from the BioDay Registry.Methods: A prospective observational study of adult patients with HE, treated for AD with dupilumab. Patients with a HE severity of at least moderate at baseline were considered for analysis. Patients with other concomitantly systemic immunosuppressive treatments were excluded. Clinical effectiveness on HE severity, using the Hand Eczema Severity Index (HECSI) and photographic guide, and health‐related quality of life, using the Quality of Life in Hand Eczema Questionnaire (QOLHEQ), were evaluated.Results: A total of 72 patients were included. HECSI‐75 was achieved by 54/62 patients (87.1%) and HECSI‐90 by 39/72 (62.9%) at 52 weeks. Based on the photographic guide, 56/62 patients (90.3%) achieved the endpoint of ‘clear’ or ‘almost clear’. Mean QOLHEQ reduction was −63.5% (95% confidence interval −38.23 to −27.41). There was no difference in response between HE subtypes.Conclusions: The results from this study hold promise for dupilumab to be a suitable treatment option for isolated CHE.
- 24 April 2022
- Published by Wiley in Contact Dermatitis
- Vol. 87 (2) , 185-191
Open AccessThe long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry
Background: The hands are a common predilection site of atopic dermatitis (AD). Dupilumab is licensed for the treatment of AD but not for chronic hand eczema (CHE), while CHE is challenging to treat.Objectives: To evaluate the long‐term effect of dupilumab on hand eczema (HE) in patients with AD from the BioDay Registry.Methods: A prospective observational study of adult patients with HE, treated for AD with dupilumab. Patients with a HE severity of at least moderate at baseline were considered for analysis. Patients with other concomitantly systemic immunosuppressive treatments were excluded. Clinical effectiveness on HE severity, using the Hand Eczema Severity Index (HECSI) and photographic guide, and health‐related quality of life, using the Quality of Life in Hand Eczema Questionnaire (QOLHEQ), were evaluated.Results: A total of 72 patients were included. HECSI‐75 was achieved by 54/62 patients (87.1%) and HECSI‐90 by 39/72 (62.9%) at 52 weeks. Based on the photographic guide, 56/62 patients (90.3%) achieved the endpoint of ‘clear’ or ‘almost clear’. Mean QOLHEQ reduction was −63.5% (95% confidence interval −38.23 to −27.41). There was no difference in response between HE subtypes.Conclusions: The results from this study hold promise for dupilumab to be a suitable treatment option for isolated CHE.
- Open Access
- 5 January 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102, adv00626
Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study
Data on chronic hand eczema and severity of hand eczema in the general population is scarce. In this cross-sectional study, a questionnaire was sent to 135,950 Lifelines Cohort Study participants, in order to investigate the prevalence and severity of hand eczema in the Dutch general population. In total, 57,798 subjects were included. The lifetime prevalence of hand eczema was 15.0% (95% confidence interval 14.7–15.3), the 1-year prevalence 7.3% (95% confidence interval 7.1–7.6), and the self-reported physician-diagnosed prevalence 6.1% (95% confidence interval 5.9–6.3). The 1-year prevalence of chronic hand eczema was 4.7% (95% confidence interval 4.5–4.9). The majority (56.9%) of the subjects with hand eczema had almost clear at worst ever and the prevalence of severe to very severe hand eczema at worst ever in the general population was 1.9% (95% confidence interval 1.8–2.1). Future epidemiological studies in the general population should include data about chronic hand eczema and severity of hand eczema, as this can provide perspective on the burden of hand eczema.
- 5 January 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102, adv00626
Open AccessPrevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study
Data on chronic hand eczema and severity of hand eczema in the general population is scarce. In this cross-sectional study, a questionnaire was sent to 135,950 Lifelines Cohort Study participants, in order to investigate the prevalence and severity of hand eczema in the Dutch general population. In total, 57,798 subjects were included. The lifetime prevalence of hand eczema was 15.0% (95% confidence interval 14.7–15.3), the 1-year prevalence 7.3% (95% confidence interval 7.1–7.6), and the self-reported physician-diagnosed prevalence 6.1% (95% confidence interval 5.9–6.3). The 1-year prevalence of chronic hand eczema was 4.7% (95% confidence interval 4.5–4.9). The majority (56.9%) of the subjects with hand eczema had almost clear at worst ever and the prevalence of severe to very severe hand eczema at worst ever in the general population was 1.9% (95% confidence interval 1.8–2.1). Future epidemiological studies in the general population should include data about chronic hand eczema and severity of hand eczema, as this can provide perspective on the burden of hand eczema.
- Top Cited Papers
- 30 December 2021
- Published by Wiley in Contact Dermatitis
- Vol. 86 (5) , 357-378
Guidelines for diagnosis, prevention, and treatment of hand eczema
Background: Hand eczema is a common inflammatory skin disorder. Health care providers need continuously updated information about the management of hand eczema to ensure best treatment for their patients.Objectives: To update the European Society of Contact Dermatitis guideline on the diagnosis, prevention, and treatment on of hand eczema.Method: The Guideline Development Group (GDG) was established on behalf of the ESCD. A call for interest was launched via the ESCD website and via the ESCD members' mailing list. Appraisal of the evidence for therapeutic and preventive interventions was applied and a structured method of developing consensus was used and moderated by an external methodologist. The final guideline was approved by the ESCD executive committee and was in external review on the ESCD webpage for 1 month.Results: Consensus was achieved for several statements and management strategies.Conclusion: The updated guideline should improve management of hand eczema.
- 30 December 2021
- Published by Wiley in Contact Dermatitis
- Vol. 86 (5) , 357-378
Top Cited PapersGuidelines for diagnosis, prevention, and treatment of hand eczema
Background: Hand eczema is a common inflammatory skin disorder. Health care providers need continuously updated information about the management of hand eczema to ensure best treatment for their patients.Objectives: To update the European Society of Contact Dermatitis guideline on the diagnosis, prevention, and treatment on of hand eczema.Method: The Guideline Development Group (GDG) was established on behalf of the ESCD. A call for interest was launched via the ESCD website and via the ESCD members' mailing list. Appraisal of the evidence for therapeutic and preventive interventions was applied and a structured method of developing consensus was used and moderated by an external methodologist. The final guideline was approved by the ESCD executive committee and was in external review on the ESCD webpage for 1 month.Results: Consensus was achieved for several statements and management strategies.Conclusion: The updated guideline should improve management of hand eczema.
- Open Access
- 12 July 2021
- Published by Wiley in Experimental Dermatology
- Vol. 30 (12) , 1775-1786
Vesicular hand eczema transcriptome analysis provides insights into its pathophysiology
Hand eczema is a common inflammatory skin condition of the hands whose pathogenesis is largely unknown. More insight and knowledge of the disease on a more fundamental level might lead to a better understanding of the biological processes involved, which could provide possible new treatment strategies. We aimed to profile the transcriptome of lesional palmar epidermal skin of patients suffering from vesicular hand eczema using RNA‐sequencing. RNA‐sequencing was performed to identify differentially expressed genes in lesional vs. non‐lesional palmar epidermal skin from a group of patients with vesicular hand eczema compared to healthy controls. Comprehensive real‐time quantitative PCR analyses and immunohistochemistry were used for validation of candidate genes and protein profiles for vesicular hand eczema. Overall, a significant and high expression of genes/proteins involved in keratinocyte host defense and inflammation was found in lesional skin. Furthermore, we detected several molecules, both up or downregulated in lesional skin, which are involved in epidermal differentiation. Immune signalling genes were found to be upregulated in lesional skin, albeit with relatively low expression levels. Non‐lesional patient skin showed no significant differences compared to healthy control skin. Lesional vesicular hand eczema skin shows a distinct expression profile compared to non‐lesional skin and healthy control skin. Notably, the overall results indicate a large overlap between vesicular hand eczema and earlier reported atopic dermatitis lesional transcriptome profiles, which suggests that treatments for atopic dermatitis could also be effective in (vesicular) hand eczema.
- 12 July 2021
- Published by Wiley in Experimental Dermatology
- Vol. 30 (12) , 1775-1786
Open AccessVesicular hand eczema transcriptome analysis provides insights into its pathophysiology
Hand eczema is a common inflammatory skin condition of the hands whose pathogenesis is largely unknown. More insight and knowledge of the disease on a more fundamental level might lead to a better understanding of the biological processes involved, which could provide possible new treatment strategies. We aimed to profile the transcriptome of lesional palmar epidermal skin of patients suffering from vesicular hand eczema using RNA‐sequencing. RNA‐sequencing was performed to identify differentially expressed genes in lesional vs. non‐lesional palmar epidermal skin from a group of patients with vesicular hand eczema compared to healthy controls. Comprehensive real‐time quantitative PCR analyses and immunohistochemistry were used for validation of candidate genes and protein profiles for vesicular hand eczema. Overall, a significant and high expression of genes/proteins involved in keratinocyte host defense and inflammation was found in lesional skin. Furthermore, we detected several molecules, both up or downregulated in lesional skin, which are involved in epidermal differentiation. Immune signalling genes were found to be upregulated in lesional skin, albeit with relatively low expression levels. Non‐lesional patient skin showed no significant differences compared to healthy control skin. Lesional vesicular hand eczema skin shows a distinct expression profile compared to non‐lesional skin and healthy control skin. Notably, the overall results indicate a large overlap between vesicular hand eczema and earlier reported atopic dermatitis lesional transcriptome profiles, which suggests that treatments for atopic dermatitis could also be effective in (vesicular) hand eczema.
- 23 June 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (11) , E787-E790
Prevalence of adult atopic dermatitis in the general population, with a focus on moderate‐to‐severe disease: results from the Lifelines Cohort Study
Previous epidemiologic studies on atopic dermatitis (AD) indicate a large variation (0.3-17.6%) in the prevalence of adult AD, depending on differences in the methodology, AD definitions and study population1,2. Here, we conducted a large cross-sectional study to firstly estimate the prevalence of adult AD in the Dutch general population, with a focus on moderate to severe AD.
- 23 June 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (11) , E787-E790
Prevalence of adult atopic dermatitis in the general population, with a focus on moderate‐to‐severe disease: results from the Lifelines Cohort Study
Previous epidemiologic studies on atopic dermatitis (AD) indicate a large variation (0.3-17.6%) in the prevalence of adult AD, depending on differences in the methodology, AD definitions and study population1,2. Here, we conducted a large cross-sectional study to firstly estimate the prevalence of adult AD in the Dutch general population, with a focus on moderate to severe AD.